精准医疗

Search documents
融资首发丨「凯瑞医疗」宣布完成数千万元Pre-A轮融资,加快智能采血机器人研发速度
3 6 Ke· 2025-05-28 07:42
36氪四川获悉,成都市凯瑞医疗科技有限公司(以下简称为"凯瑞医疗")近日宣布完成数千万元Pre-A轮融资,投资方为泸州市双港实业投资发展有限公司 (以下简称为"泸州双港"),是泸州市龙马潭区的产业投资平台。 智能采血机器人M1Pro 王懿刚表示,"公司本轮融资资金主要用于加快研发速度、聚焦于技术壁垒突破、人才队伍搭建、建设产线及CE注册。我们期待通过智能采血技术,缓解医 护人员高频重复工作的压力,减少医疗资源分布不均的现状。长期来看,公司将以采血机器人为起点,打造'智慧医疗工作站',覆盖从采样到检测的全流程 自动化,让精准医疗惠及更多基层场景。" 投资方泸州双港相关负责人评价道:"我们认为「凯瑞医疗」智能采血机器人在机器人采血这一细分领域有望达到国际领先水平。「凯瑞医疗」创新属性较 强,产品应用场景较广,团队研发能力扎实,期待系列产品持续创造经济效益与社会价值。" 关于泸州双港: 泸州市双港实业投资发展有限公司是四川泸州(长江)经济开发区产业投资平台,主体信用评级AA。公司以国企担当服务产业发展,作为耐心资本"投早、 投小、投长期、投硬科技",促进长开区产业提档升级和高质量发展。 「凯瑞医疗」创立于2022年 ...
9.3亿美元市场!临床质谱多领域应用突破推动精准医疗发展
仪器信息网· 2025-05-27 08:48
Core Insights - The article emphasizes the growing importance of clinical mass spectrometry in precision medicine, highlighting its unique advantages such as high specificity, sensitivity, and multi-parameter detection [3]. Market Overview - As of May 26, 2025, two clinical mass spectrometry instruments and twelve reagent kits have been approved. The global clinical mass spectrometry market is projected to reach $930 million by 2024, with an expected growth to $1.435 billion by 2029, reflecting a compound annual growth rate (CAGR) of 9% [3]. Clinical Applications - **Intraoperative Diagnosis of Brain Gliomas**: The article discusses the use of portable mass spectrometry for rapid identification of IDH mutations in brain gliomas, which significantly improves patient prognosis. A study conducted by a team from Fudan University and other institutions achieved a 100% accuracy rate in detecting IDH mutations in 697 samples from 260 glioma patients [4]. - **Therapeutic Drug Monitoring (TDM)**: Mass spectrometry is becoming a crucial tool in TDM, particularly for high-risk drugs like monoclonal antibodies. The nSMOL (nano-surface and molecular orientation limited) technology has enhanced specificity and sensitivity in measuring total drug concentrations, supporting personalized treatment for complex diseases [5]. Challenges and Future Directions - Despite the advancements, the transition of mass spectrometry from the laboratory to clinical settings faces challenges such as complex sample preparation, lack of standardized protocols, insufficient automation, and limitations in speed and cost. The article also mentions the importance of standard materials for ensuring accurate measurement in clinical chemistry [6].
基因科技赋能弱视诊疗 何氏眼科开启精准医疗新篇章
Zheng Quan Shi Bao Wang· 2025-05-26 03:16
庞继景教授指出,基因检测正逐步成为儿童视力评估常规项目,结合屈光矫正形成多维度干预体系。这 种转变使弱视治疗成功率提升30%,并为遗传性眼病患者抢抓3-12岁视觉发育黄金期。 作为国内眼健康全产业链平台,何氏眼科持续深耕基因治疗、干细胞再生医学及智能设备数据应用三大 领域。在"十四五"眼健康规划推动下,企业正通过科技创新践行"智慧光明城"战略目标,为健康中国建 设注入新动能。(燕云) (文章来源:证券时报网) 近日,何氏眼科(301103)在儿童弱视诊疗领域取得突破性进展。通过融合基因检测与视知觉学习训练技 术,成功将传统弱视诊疗模式推向精准化新阶段。 在临床实践中,遗传眼病首席科学家庞继景教授团队接诊的9岁高度近视患儿案例引发关注。通过 OPN1LW基因检测,团队发现其近视实为遗传性视网膜疾病早期表现,颠覆了传统"弱视"诊断结论。基 于此,团队创新采用视知觉学习训练:通过Gabor视标刺激视觉皮层神经可塑性,经4个月家庭化训练, 患儿右眼视力从0.7提升至0.9,屈光度发展得到有效控制。 这项技术的突破性在于构建"基因筛查-大脑重塑"双轨诊疗体系。通过排除致病基因变异确保诊断精准 性,再运用视知觉训练激活视 ...
券商力推30只潜力股!明阳智能领跑,39%上涨空间如何把握?
Sou Hu Cai Jing· 2025-05-26 02:19
Group 1 - The core viewpoint of the article highlights the recent bullish ratings from brokerages on 30 stocks, with Mingyang Smart Energy leading the list due to a target price increase of 39.88% [1][3] - The sectors with the most stocks rated include capital goods, materials, and technology hardware, indicating a focus on policy-supported areas, particularly high-end manufacturing and green energy [3][4] - Mingyang Smart Energy's strong performance is attributed to a significant increase in wind turbine exports, a recovery in profit margins, and a low valuation compared to peers [4][5] Group 2 - Other notable stocks include Dian Diagnostics, which benefits from aging demographics and precision medicine policies, and Anhui Heli, which has a strong export market and expected margin improvements [5][6] - The article suggests a strategic approach to investing, recommending gradual accumulation of stocks like Mingyang Smart Energy if it surpasses certain price levels, while also monitoring policy developments that could impact the sectors [6][7] - The current market phase is characterized by a transition from policy support to performance-driven outcomes, emphasizing the importance of companies with real orders and healthy cash flows [7]
波士顿科学Vercise Genus™ DBS系统全国上市会顺利举办
思宇MedTech· 2025-05-23 08:03
Core Viewpoint - The article highlights the advancements in Parkinson's disease treatment through the introduction of the Vercise Genus DBS system by Boston Scientific, emphasizing its potential to enhance patient outcomes and the importance of precision in treatment [2][4][5]. Group 1: Product Launch and Features - The Vercise Genus DBS system was successfully launched at the AASSFN annual meeting, providing diverse treatment options for Parkinson's disease patients in China [2]. - The system has received approval from the National Medical Products Administration and completed its first clinical applications in April 2024 [4]. - It features a unique four-channel IPG, allowing for personalized treatment solutions by covering more targets and addressing varying patient symptoms [5]. Group 2: Clinical Efficacy - A five-year multicenter clinical study indicated that the DBS system improved motor function in Parkinson's patients by 51%, with an increase of 6 hours in daily "on" time compared to pre-treatment [5]. - The quality of life for participating patients improved by 34% as a result of the treatment [5]. Group 3: Technological Innovations - The DBS therapy's effectiveness relies heavily on precise implantation and modulation of target neural nuclei, aided by the system's directional electrode design and MICC technology [6]. - The visualization control system allows doctors to see real-time changes in stimulation fields, enhancing treatment efficiency and reducing programming time by an average of 56% [6]. - The rechargeable IPG boasts an impressive lifespan of up to 25 years, significantly reducing the need for additional surgeries and providing a stable treatment experience [6].
诊断治疗双突破:环状核酸引领精准医疗新浪潮
生物世界· 2025-05-21 07:35
近年来, 环状寡核苷酸 凭借 其独特的闭环结构和卓越的生物稳定性, 逐渐 成为生物医学领域的研究热 点。这类分子主要包括 环状 RNA (circRNA) 和 环状单链 DNA ( C ssDNA) ,在疾病诊断和治疗中 展现出广阔的应用前景,正推动精准医疗 迈向新高度 。 环状寡核苷酸为何备受 瞩目 ? 1、 疫苗 开发 :利用 circRNA 编码抗原蛋白,并通过脂质纳米颗粒封装后注射到体内。circRNA 进入细 胞后翻译出相应的抗原蛋白,最终由抗原递呈细胞 (APC) 呈递,引发免疫应答。 2、 基因表达调控 : 合成具有特定功能的 circRNA,例如 miRNA 海绵、蛋白海绵、基因沉默等。通过纳 米颗粒递送到靶细胞后,这些 circRNA 可在细胞内执行相应的基因调控功能。 3、 细胞治疗 :利用 circRNA 编码 CAR (嵌合抗原受体) 或 TCR (T 细胞受体) 结构蛋白,并封装于 靶向纳米颗粒中。通过静脉注射,可直接在体内原位生成 CAR-T 或 TCR-T 细胞,无需复杂的体外病毒改 造过程, 能够显著 提高开发效率、降低开发成本。 环状寡核苷酸 ( Circular Oligo ...
浙江湖州出台加快推动招商场景建设实施方案
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-05-19 08:16
浙江省湖州市近日出台《湖州市加快推动招商场景建设实施方案》,以"场景创新 赋能产业"为主题, 按照"为场景找技术、为技术找场景"双找路径,推动科技创新和产业创新深度融合,加快构建千亿级产 业生态。 根据《方案》,湖州市将围绕产业链强链补链、新兴产业壮大、传统产业升级、未来产业培育及智慧城 市建设五大方向,系统性构建招商场景生态。到2027年,全市计划累计建成具有地方特色的场景建设示 范园区(楼宇)10个以上,打造产业转型升级标杆场景6个以上,为高质量发展注入强劲动能。 为实现目标落地,湖州市将强化要素保障,对重大场景项目优先配置土地、能耗等资源;每年举办招商 场景发布活动10次以上,开展应用大赛、推介会等专项活动,推动不少于20项新技术、新产品项目落 地。目前,首批15个标志性场景和25个标志性招商场景项目已发布,覆盖绿色生态、低空经济、人工智 能等领域,总投资规模超百亿元。 在重点产业领域,湖州市将聚焦新能源汽车及关键零部件、半导体及光电、智能物流装备等新兴产业 链,依托链主型企业牵引,构建"龙头企业+应用场景+中小企业+科研机构"协同模式。其中,新能源汽 车领域将以领军企业为核心,推动汽车电子、智能网联等 ...
精准医疗头部企业成都基地一期完工
Sou Hu Cai Jing· 2025-05-18 00:47
Group 1: GE Healthcare and Precision Medicine - GE Healthcare's China Precision Medicine Industrial Base Phase I has been completed, promoting the localization of high-end equipment and innovation in precision medicine [5] - The project focuses on the production of key nuclear medicine imaging equipment, specifically cyclotrons, to drive innovation in the precision medicine industry chain [5] - GE Healthcare plans to enhance investment in talent, technology, and scale in Sichuan, expanding production lines to cover the entire nuclear medicine imaging chain [5] Group 2: Ruixing Jiuyu Gas Equipment - Ruixing Jiuyu Gas Equipment's new R&D center in Chengdu is set to be operational next month, aimed at upgrading gas equipment products and enhancing market share [4][6] - The R&D center, covering approximately 3,000 square meters, will feature advanced equipment such as 3D printers and performance testing platforms [6] - The company has committed to investing 5% of its annual sales revenue into product R&D to strengthen its core competitiveness [6] Group 3: Guoyao Tianyu Zhigu Project - The Guoyao Tianyu Zhigu project, with a total investment of 3 billion yuan and covering 163 acres, has officially commenced construction [7] - This project is the first third-generation smart industrial park established by Guoyao Group in Southwest China, focusing on healthcare, electronic information, equipment manufacturing, and new materials [7] - The project aims for overall delivery by mid-2027 and will include talent apartments and a supply chain finance center to create an integrated ecosystem [8]
沙利文:2024年AI生命组学市场研究报告
Sou Hu Cai Jing· 2025-05-17 05:49
今天分享的是:沙利文:2024年AI生命组学市场研究报告 报告共计:18页 一、行业定义与核心特征 AI生命组学以多组学数据为基础,通过AI算法实现数据的高效管理与挖掘、多维度整合分析及疾病机理解析。其关键特征包 括: - 数据智能处理:针对临床队列数据的高维度、高噪声特性,AI技术可自动完成降维、去噪和特征选择,优化专病队列设计,加 速生物标志物发现。 - 多组学整合分析:整合DNA测序、RNA表达谱、代谢物谱等多源数据,通过算法融合不同层面信息,揭示基因调控网络与代 谢途径的动态关联。 - 疾病与药物研究赋能:在致病机理研究中,AI通过对比患者与健康个体数据识别分子标志物;在药物开发中,支持靶点发现、 抗体优化及虚拟筛选,显著缩短研发周期。 - 个性化医疗应用:基于患者组学数据与临床病史,AI提供定制化治疗方案,覆盖肿瘤免疫疗法、罕见病诊断等领域,提升治疗 精准度。 二、市场分类与产业链布局 AI生命组学市场分为五大核心领域: 1. AI队列数据中心解决方案:智能化管理临床数据与样本,优化患者招募和试验设计,提升研究效率。 《2024年AI生命组学市场研究报告》核心内容总结 AI生命组学作为生命科学与人工 ...
Volition(VNRX) - 2025 Q1 - Earnings Call Transcript
2025-05-16 13:30
Financial Data and Key Metrics Changes - Total operating expenses for Q1 2025 declined by 35% compared to Q1 2024, reflecting strong cost management across all spending categories [5][6][8] - Net cash used in operating activities was £4.3 million for Q1 2025, down from £8.3 million in Q1 2024, indicating improved cash flow management [6][10] - Revenue for the quarter was approximately $250,000, representing a 44% increase year-on-year, including the first revenue from human product sales [6][7][8] - Cash and cash equivalents at the end of Q1 2025 totaled approximately $2.6 million, down from $3.3 million at the end of 2024 [7] Business Line Data and Key Metrics Changes - The Nu. Q technology is being commercialized in the human diagnostic market, with significant licensing discussions ongoing with over 10 companies [11][12] - The Nu. Q cancer diagnostic pillar is progressing, with two major companies in active negotiations and a pivotal lung cancer screening study in Taiwan enrolling over 100 patients [14][15] - The Nu. Q NETs technology is also advancing, with a total addressable market for testing and monitoring intensive care patients estimated at $1 billion annually [17][18] Market Data and Key Metrics Changes - The combined market value of seven companies in licensing discussions exceeds $600 billion, highlighting the potential reach of the technology [12] - The total addressable market for cancer and sepsis diagnostics is estimated at $25 billion annually, presenting substantial revenue opportunities [12] Company Strategy and Development Direction - The company aims to achieve cash neutrality for the full year 2025, with a focus on reducing expenses and securing multiple licensing agreements in the human diagnostic space [5][10][36] - The strategy includes leveraging existing partnerships and expanding the global reach of the Nu. Q Vet cancer test while automating central labs to enhance revenue growth [24][25][36] - The company is focused on commercializing its technology quickly to make it accessible worldwide, with a mission to save lives and improve outcomes [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining low operating costs while focusing on commercialization efforts [41][44] - The company is optimistic about the progress made in licensing discussions and the potential for significant revenue generation from ongoing clinical studies [33][36] Other Important Information - The company recorded its first revenue from a regulated human product in the EU, marking a significant milestone [72] - Discussions are ongoing with several national lung screening programs, indicating strong interest in the company's diagnostic solutions [34] Q&A Session Summary Question: Is the current low level of operating expenses sustainable for the rest of 2025? - Management confirmed that maintaining low costs is a priority and that they have made significant progress in controlling expenses across all categories [41][42][44] Question: Update on the progress of the feline cancer test? - Management reported that pre-analytics work for the feline cancer test has been completed, and clinical data collection is underway [45][48] Question: What is the operational engagement with partners like Texas A&M and IDEXX? - Management indicated that while they know the volume of purchases, detailed sales flow information is typically not shared due to commercial sensitivity [54][55] Question: Will marketing expenses remain flat for the rest of the year? - Management stated that while they plan to spend less overall, there may be fluctuations in spending due to conference attendance and other marketing activities [58][60] Question: When will revenues from the human study contract in Nu. Q Discover be recognized? - Management noted that the clinical study will run over two years, with revenues expected to be spread out over that period [64][65]